Effects of Hepatic Impairment on the Pharmacokinetic Profile and Safety of Lobeglitazone
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Pharmacology in Drug Development"
DOI: 10.1002/cpdd.1045
Abstract: In this open‐label, single‐dose, parallel‐group study, we compared the pharmacokinetic profile and safety of lobeglitazone, a thiazolidinedione acting as an agonist for peroxisome proliferator‐activated receptors, in patients with hepatic impairment (HI) and healthy matched controls… read more here.
Keywords: profile safety; safety lobeglitazone; lobeglitazone; pharmacokinetic profile ... See more keywords
Lobeglitazone attenuates fibrosis in corneal fibroblasts by interrupting TGF-beta-mediated Smad signaling
Sign Up to like & getrecommendations! Published in 2021 at "Graefe's Archive for Clinical and Experimental Ophthalmology"
DOI: 10.1007/s00417-021-05370-2
Abstract: Transforming growth factor beta 1 (TGF-β1) is an important cytokine released after ocular surface injury to promote wound healing. However, its persistence at the injury site triggers a fibrotic response that leads to corneal scarring… read more here.
Keywords: effect; tgf; tgf induced; corneal fibroblasts ... See more keywords
Structural Basis for the Enhanced Anti-Diabetic Efficacy of Lobeglitazone on PPARγ
Sign Up to like & getrecommendations! Published in 2017 at "Scientific Reports"
DOI: 10.1038/s41598-017-18274-1
Abstract: Peroxisome proliferator-activated receptor γ (PPARγ) is a member of the nuclear receptor superfamily. It functions as a ligand-activated transcription factor and plays important roles in the regulation of adipocyte differentiation, insulin resistance, and inflammation. Here,… read more here.
Keywords: ppar; structural basis; anti diabetic; basis enhanced ... See more keywords
The Antidiabetic Drug Lobeglitazone Protects Mice From Lipogenesis-Induced Liver Injury via Mechanistic Target of Rapamycin Complex 1 Inhibition
Sign Up to like & getrecommendations! Published in 2018 at "Frontiers in Endocrinology"
DOI: 10.3389/fendo.2018.00539
Abstract: Non-alcoholic fatty liver disease (NAFLD) is a metabolic disorder closely linked with type II diabetes (T2D). The progression of NAFLD is associated with the induction of lipogenesis through hyperactivation of the mechanistic target of rapamycin… read more here.
Keywords: lipogenesis; drug; mechanistic target; liver injury ... See more keywords
Lobeglitazone, a Novel Peroxisome Proliferator-Activated Receptor γ Agonist, Attenuates Renal Fibrosis Caused by Unilateral Ureteral Obstruction in Mice
Sign Up to like & getrecommendations! Published in 2017 at "Endocrinology and Metabolism"
DOI: 10.3803/enm.2017.32.1.115
Abstract: Background Renal tubulointerstitial fibrosis is a common feature of the final stage of nearly all cause types of chronic kidney disease. Although classic peroxisome proliferator-activated receptor γ (PPARγ) agonists have a protective effect on diabetic… read more here.
Keywords: peroxisome proliferator; fibrosis; renal fibrosis; mice ... See more keywords